Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Radiotherapy

PSA nadir predicts long-term mortality

The effect of PSA level on distant metastases and cause-specific mortality was assessed in a recent study, and showed a nadir PSA level 1.5 ng/ml within 2 years of radiotherapy treatment predicts distant metastases and death from prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Graph that illustrates the '24 month' nadir PSA versus 'global' nadir PSA.

References

  1. Zelefsky, M. J. et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int. J. Radiat. Oncol. Biol. Phys. 75, 1350–1356 (2009).

    Article  Google Scholar 

  2. The NCCN Clinical Practice Guidelines in Oncology Prostate Cancer (Version 1.2010) [online]. (2010).

  3. Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Uzzo, R. G. & Pollack, A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 61, 1291–1298 (2005).

    Article  CAS  Google Scholar 

  4. Zietman, A. L. et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1–2 adenocarcinoma of the prostate. Radiother. Oncol. 40, 159–162 (1996).

    Article  CAS  Google Scholar 

  5. Lee, W. R., Hanlon, A. L. & Hanks, G. E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J. Urol. 156, 450–453 (1996).

    Article  CAS  Google Scholar 

  6. Cavanaugh, S. X. et al. Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. Prostate Cancer Prostatic Dis. 8, 353–358 (2005).

    Article  CAS  Google Scholar 

  7. Ray, M. E. et al. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 68, 1257–1262 (2006).

    Article  Google Scholar 

  8. Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M. & Pollack, A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109, 41–47 (2007).

    Article  CAS  Google Scholar 

  9. Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M. & Pollack, A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70, 59–66 (2008).

    Article  CAS  Google Scholar 

  10. Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R. & Williams, S. G. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75, S103–S104 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buyyounouski, M. PSA nadir predicts long-term mortality. Nat Rev Clin Oncol 7, 188–190 (2010). https://doi.org/10.1038/nrclinonc.2010.33

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.33

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing